May 29, 2020 10:00 AM EDTUpdated 11:01 AM

Sierra Oncology brings on former Aimmune CEO to the helm; Flagship woos ex-Novartis exec Fabrice Chouraqui

Kathy Wong

Editor

Alex Hoffman

Copy Chief

→ Momelotinib-focused Sierra Oncology, which launched a Phase III trial in November for myelofibrosis patients, has made Stephen Dilly its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sierra Oncology brings on former Aimmune CEO to the helm; Flagship woos ex-Novartis exec Fabrice Chouraqui

Kathy Wong

Editor

Alex Hoffman

Copy Chief

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Sier­ra On­col­o­gy brings on for­mer Aim­mune CEO to the helm; Flag­ship woos ex-No­var­tis ex­ec Fab­rice Chouraqui

Editor

Copy Chief

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sierra Oncology brings on former Aimmune CEO to the helm; Flagship woos ex-Novartis exec Fabrice Chouraqui